Taipei, July 22 (CNA) A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
More infections reported as Taiwan enters flu season: CDC
09/26/2023 10:15 PM - Society
Temp worker sentenced to 6 months for fire at Carrefour warehouse
09/26/2023 09:56 PM - Business
Hon Hai increases investment in U.S.-based AI startup
09/26/2023 09:17 PM - Business
Google says undersea cables created over 64,000 jobs in Taiwan
09/26/2023 08:38 PM - Sports
Taiwanese women's taekwondo athletes win silver medals at Asian Games
09/26/2023 08:20 PM